The medicine that help us: Maxalt.

Maxalt: uses Maxalt is used to treat migraines. It helps to relieve headaches, pain and other symptoms of migraines, including sensitivity to light/sound, nausea, and vomiting. Prompt treatment allows you to get back to your normal routine and may decrease your need for other pain medications. Maxalt doesn't prevent future migraines or reduce how often you may get a headache.

Maxalt belongs to a group of drugs called triptans. It affects a certain natural chemical ( serotonin ) that constricts blood vessels in the brain. It may also block other pain pathways in brain.

Maxalt: how to use Read Patient Information Leaflet available from your pharmacist before we start using Maxalt and each time you get a refill. Ask your doctor or pharmacist if we have any questions.

Take Maxalt by mouth at first sign of a migraine, or as directed by your doctor. It may be taken with or without food, although faster relief may occur while use Maxalt when it's taken on an empty stomach. Do not take Maxalt to prevent a migraine. If there is no improvement in your symptoms, don't take any more doses of Maxalt before talking to your doctor.

If your symptoms are only partly relieved, or if your headache comes back, we may take a second dose after 2 hours or as directed by your doctor. Do not take more than 30 milligrams ( 3 doses ) in a 24-hour period. If you also take propranolol, do not take more than 15 milligrams of Maxalt in a 24-hour period. For the Canadian product: according to the drug manufacturer, do not exceed 20 mg in a 24 hour period.

If we have never taken Maxalt before and we have risk factors for heart disease ( see Precautions ) , you may be advised to take your first dose in your doctor's office in order to monitor for rare but serious heart problems ( e. g. , heart attack ) .

Your dosage is based on your medical condition and response to therapy. Tell your doctor if your condition doesn't improve or if it worsens.

Maxalt: side effects Drowsiness, dizziness, dry mouth, numbness/tingling/prickling sensations, redness ( flushing ) , tiredness/weakness may occur while use Maxalt. If these effects persist or worsen, notify your doctor promptly.

Remember that your doctor has prescribed Maxalt because he or she has judged that benefit to we is greater than the risk of side effects. Many people using Maxalt do not have serious side effects.

Chest/jaw/neck tightness can commonly occur shortly after using Maxalt. Only rarely are these signs of a serious condition. However, you mayn't be able to tell this apart from a serious reaction related to a lack of blood flow to heart, brain or other parts of body. Seek immediate medical attention if any of these unlikely but very serious ( rarely fatal ) side effects occur:

Tell your doctor immediately if any of these unlikely but serious side effects occur:

Maxalt may rarely cause a very serious condition called serotonin syndrome. The risk increases when Maxalt is taken with certain other drugs such as other " triptans " used to treat migraine headaches ( e. g. , sumatriptan, zolmitriptan ) , certain antidepressants including SSRIs ( e. g. , citalopram, fluoxetine, paroxetine ) and NSRIs ( e. g. , duloxetine, venlafaxine ) , or a certain drug to treat obesity ( sibutramine ) . Before taking Maxalt, tell your doctor if we take any of these medications. Serotonin syndrome may be more likely when you start or increase dose of any of these medications. Seek immediate medical attention if we develop some of following symptoms:

In unlikely event we have a serious allergic reaction to Maxalt, seek immediate medical attention. Symptoms of a serious allergic reaction include:

This isn't a complete list of possible side effects. If we notice other effects not listed above, contact your doctor or pharmacist.

Maxalt: precautions See also How to Use section.

Before taking Maxalt, tell your doctor or pharmacist if we are allergic to it; or to other triptan migraine drugs; or if we have any other allergies.

Maxalt should not be taken if we have certain medical conditions. Before using Maxalt, consult your doctor or pharmacist if you have a history of:

Before using Maxalt, tell your doctor or pharmacist your medical history, especially of:

Tell your doctor if we have following risk factors for heart disease:

If we are at high risk for heart disease, your doctor may want to check your heart before prescribing Maxalt.

Maxalt may make you dizzy or drowsy; use caution engaging in activities requiring alertness such as driving or using machinery. Limit alcoholic beverages.

Maxalt should be used only when clearly needed during pregnancy. Discuss the risks and benefits with your doctor.

It isn't known whether Maxalt passes into breast milk. Consult your doctor before breast-feeding.

Maxalt: interactions Your healthcare professionals ( e. g. , doctor or pharmacist ) may already be aware of any possible drug interactions and may be monitoring you for it. Don't start, stop or change the dosage of any medicine before checking with them first.

Maxalt shouldn't be taken with the following medication because very serious interactions may occur while use Maxalt:

Avoid taking MAO inhibitors ( e. g. , furazolidone, isocarboxazid, linezolid, moclobemide, phenelzine, procarbazine, rasagiline, selegiline, tranylcypromine ) for 2 weeks before, during, and after treatment with Maxalt. In some cases a serious, possibly fatal drug interaction may occur while use Maxalt.

If you're currently using any of these medications listed above, tell your doctor or pharmacist before starting Maxalt.

Before using Maxalt, tell your doctor or pharmacist of all prescription and nonprescription/herbal products we may use, especially of:

If we also take any ergotamine medication ( e. g. , dihydroergotamine or methysergide ) or any other " triptan " drugs ( e. g. , zolmitriptan, sumatriptan ) , we will need to separate your Maxalt dose from your dose of these other medications in order to lessen chance of serious side effects. Ask your doctor how long we should wait between your doses of these drugs.

Tell your doctor or pharmacist if we also take drugs that cause drowsiness such as: certain antihistamines ( e. g. , diphenhydramine ) , anti-seizure drugs ( e. g. , carbamazepine ) , medicine for sleep or anxiety ( e. g. , alprazolam, diazepam, zolpidem ) , muscle relaxants, narcotic pain relievers ( e. g. , codeine ) , psychiatric medicines ( e. g. , chlorpromazine, amitriptyline, risperidone, trazodone ) .

Check labels on all your medicines ( e. g. , cough-and-cold products ) because they may contain drowsiness-causing ingredients. Ask your pharmacist about safe use of those products.

This document does not contain all possible interactions. Therefore, before using Maxalt, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you, and share list with your doctor and pharmacist.

Maxalt: overdose If overdose of Maxalt is suspected, contact your local poison control center or emergency room immediately. US residents can call US national poison hotline at 1-800-222-1222. Canadian residents should call their local poison control center directly.

Maxalt: notes Take Maxalt only as needed when a migraine occurs, as directed by your doctor. Maxalt should not be taken on a regular schedule. Never increase your dose of Maxalt or take it more often than prescribed by your doctor.

Certain foods/beverages or food additives ( e. g. , red wine, cheese, chocolate, monosodium glutamate ) as well as some lifestyle patterns ( e. g. , irregular eating/sleeping habits, stress ) may bring about a migraine headache. Avoiding these " triggers " may help decrease frequency of migraine headaches. Consult your doctor for more details.

Don't share Maxalt with others.

Maxalt: missed dose Not applicable.

Maxalt: storage Store Maxalt at room temperature between 59-86 degrees F ( 15-30 degrees C ) away from light and moisture. Don't store Maxalt in bathroom. Keep all medications away from children and pets.

Properly discard Maxalt when it's expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

Delivery options for Maxalt

Breakthrough Research In Multiple Myeloma Treatment Flows From IMBCR, The Sole Independent Myelema Research Institute

The Institute for Myeloma and Bone Cancer Research ( IMBCR ) , established in 2004 as a 501 c ( 3 ) non-profit organization, is headquartered in West Hollywood, California. IMBCR is the only independent non-profit cancer research institute working to find improved treatment, and ultimately a cure for multiple myeloma, a cancer of blood cells that reside in bone marrow.

Longevity study's findings

According to American Cancer Society ( ACS ) there are approximately 45, 000 people in United States living with multiple myeloma, and estimates that approximately 14, 600 new cases of myeloma are diagnosed each year. It follows from here that average survival at diagnosis is about three years. The 5-year relative survival rate for multiple myeloma is around 33%. Also, survival is higher in younger people and lower in elderly ( 1 ) .

The International Staging System ( ISS ) has also been used to predict multiple myeloma survival. It shows a median overall survival of 62 months for stage 1 disease, 44 months for stage 2 disease, and 29 months for stage 3 disease ( 2 ) .

In 2007, data was compiled from 100 multiple myeloma patients treated with various combinations of innovative therapeutic agents ( 3 ) . These patients were treated by oncologist, James R. Berenson, MD the Medical and Scientific Director of IMBCR.

The median overall survival of these patients was 117 months, or 9. 75 years from diagnosis. The 5-year survival was approximately 80%. These numbers far surpass those predicted by the ACS and ISS demonstrating effectiveness of newer combination therapy used in Doctor Berenson's clinic.

Breakthrough Research, IMBCR tests drug compounds both in vivo and in vitro

Because of our unique position as the only independent cancer research institute dedicated to myeloma, we've accomplished several breakthroughs over last year.

1. Identified a new target that when blocked will treat myeloma directly and stop early blood vessels that feed myeloma.

2. Developed a peptide that blocks myeloma growth directly as well as stops bone loss in myeloma patients.

3. By using IMBCR proprietary animal models, optimized many different combinations of chemotherapy with new anti-myeloma drugs that'll be tested in clinical trials.

4. Tested genetic constructs that'll ONLY target myeloma cells and leave rest of body unaffected, this ongoing initiative is called, " The Cure Myeloma Project " under the guidance of lead scientist, Zhi-Wei Li, Ph. D. who joined our staff in January 2008 from Lee Moffitt Cancer Center affiliated with university of South Florida.

Presentations and Publications

Our research findings have been presented at annual meetings of American Society of Clinical Oncologists ( ASCO ) , American Association for Cancer Research, American Society of Hematology and bi-annual International Myeloma Workshop in Greece. Our research has been published in publications including, Blood, Journal of Clinical Oncology, Proceedings of National Academy of Sciences, Cancer, Clinical Cancer Research, Clinical Lymphoma and Myeloma, Oncogene, and the British Journal of Haematology.

References

1. American Cancer Society: Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society, 2007. Also available online. Last accessed September 7, 2007.

2. Greipp PR, San Miguel J, Durie BG et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-20.

3. Berenson JR, Yellin O, Crowley J et al. Factors That Determine Overall Survival among Patients ( Pts ) with Multiple Myeloma ( MM ) Treated with Zoledronic Acid ( ZOL ) : Lack of Skeletal-Related Events ( SREs ) and Occurrence of Osteonecrosis of Jaw ( ONJ ) Predict Improved Survival. Blood 2007; 110: 4842.

Rogers & Associates 1875 Century Park East, Ste 300 Los Angeles, CA 90067 United States http: //www. rogersassoc. com

Helpful healthcare tips by many topics wait you.

Bayer Removes Remaining Trasylol Stock. Bayer will begin removing the remaining Trasylol, a drug used to control bleeding during heart surgery, from the U.S. market.

Pet Turtles: Cute But Contaminated with Salmonella. FDA warns about the risk of illness from pet turtles.

Strengthening Beef Safety. An FDA regulation further protects consumers of beef against mad cow disease.

Beware of Online Cancer Fraud. FDA and the Federal Trade Commission have launched a program targeting online health fraud that takes advantage of people with cancer. Protect yourself with this advice.